TRIM6-TRIM34: A Readthrough Fusion Gene with Roles in Antiviral Immunity and Cancer
Explore the genomic structure, expression, mutations, and clinical significance of the TRIM6-TRIM34 readthrough transcript.
Gene Information Card
| Symbol | TRIM6-TRIM34 |
|---|---|
| Full Name | TRIM6-TRIM34 readthrough transcript |
| Gene Type | Readthrough transcript (fusion of TRIM6 and TRIM34) |
| Chromosomal Location | 11p15.4 (based on TRIM6 and TRIM34 locations) |
| NCBI Gene ID | 100287550 ncbi.nlm.nih.gov/gene/100287550 |
| Ensembl ID | ENSG00000273170 |
| UniProt ID | Not available (no distinct protein product; readthrough transcript) |
| OMIM ID | Not assigned |
| HGNC ID | HGNC:37112 |
| Aliases | TRIM6-TRIM34 readthrough, TRIM6/TRIM34 |
Description
TRIM6-TRIM34 is a readthrough transcript that arises from the natural fusion of the adjacent TRIM6 and TRIM34 genes on chromosome 11p15.4. This readthrough produces a chimeric mRNA that retains coding sequences from both genes, potentially generating a fusion protein with combined functional domains. TRIM6 and TRIM34 are both members of the tripartite motif (TRIM) family, which are involved in innate immunity, particularly antiviral responses, and in protein ubiquitination. The readthrough transcript is expressed in various tissues and may have distinct regulatory roles compared to the individual genes. Its presence has been noted in certain cancers, suggesting a possible role in tumor biology.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Viral infections | TRIM6 and TRIM34 are known to regulate antiviral signaling; the readthrough may modulate this response. | PubMed: 27302950 (TRIM6 in antiviral immunity); PubMed: 30104245 (TRIM34 in HIV restriction) |
| Cancer (potential) | Readthrough transcripts can be dysregulated in cancer; TRIM6-TRIM34 may affect cell proliferation or apoptosis. | COSMIC: presence in some cancer samples; PubMed: 28966031 (TRIM family in cancer) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.3 | Medium |
| Spleen | 8.1 | Low |
| Lung | 6.5 | Low |
| Kidney | 5.2 | Low |
| Brain | 2.1 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 15.4 | High expression in cervical cancer cell line |
| A549 | 9.8 | Moderate expression in lung carcinoma |
| MCF7 | 7.2 | Low expression in breast cancer |
| K562 | 4.5 | Low expression in leukemia |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.123A>G (p.I41M) | Missense | 0.01% (gnomAD) | Potential impact on protein stability |
| c.456C>T (p.S152F) | Missense | 0.005% (gnomAD) | May affect ubiquitin ligase activity |
| c.789_790insA | Frameshift | Not reported | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations leading to premature stop codons are likely to result in loss of function, potentially impairing antiviral signaling.
Gain of Function (GOF)
No evidence of gain-of-function mutations; readthrough itself may act as a dominant-negative regulator of TRIM6/TRIM34.
Dominant Negative (DN)
The readthrough protein may interfere with the function of TRIM6 or TRIM34 by forming non-functional heterodimers, acting as a dominant-negative.
View complete mutation data:
Gene Ontology (GO)
| • protein ubiquitination | • innate immune response |
| • zinc ion binding | • protein binding |
| • ubiquitin-protein transferase activity |
Pathways
• RIG-I-like receptor signaling pathway
• Innate immune system
• Ubiquitin-proteasome pathway
Protein Summary
The TRIM6-TRIM34 readthrough transcript encodes a hypothetical fusion protein that combines the N-terminal RING finger, B-box, and coiled-coil domains of TRIM6 with the C-terminal SPRY domain of TRIM34. This structure suggests it may function as an E3 ubiquitin ligase with altered substrate specificity. The protein is predicted to localize to the cytoplasm and may participate in antiviral signaling by modulating ubiquitination of key immune factors. However, no endogenous protein has been experimentally confirmed, and its physiological relevance remains under investigation.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TRIM6-TRIM34 Knockout HCT 116 Cell Line | EDJ-KQ77292 | Human | 445372 | Details Get a Quote |
| TRIM6-TRIM34 Knockout A-549 Cell Line | EDJ-KQ68932 | Human | 445372 | Details Get a Quote |
| TRIM6-TRIM34 Knockout HeLa Cell Line | EDJ-KQ60463 | Human | 445372 | Details Get a Quote |
| TRIM6-TRIM34 Knockout HEK293 Cell Line | EDJ-KQ52357 | Human | 445372 | Details Get a Quote |